The distinctions between obesity-induced features occurring in the entire adipocyte population versus specific adipocyte subpopulations may explain the outstanding effectiveness of PPARγ agonists, such as thiazolidinediones (TZDs), in improving adipose function and glucose homeostasis37, surpassing the effects of other anti-inflammatory or anti-stress reagents43–45. This evidence concerns the gene PPARG and obesity disorder.